221-21 | Study of Durvalumab With Stereotactic Body Radiation Therapy (SBRT)

Overview

“A Phase III, Randomized, Placebo-controlled, Double-blind, Multi-center, International Study of Durvalumab With Stereotactic Body Radiation Therapy (SBRT) for the Treatment of Patients With Unresected Stage I/II, Lymph-node Negative Non-small Cell Lung Cancer (PACIFIC-4/RTOG-3515)”

The purpose of this study is to find out if durvalumab will work and be safe for the treatment of participants with Stage I/II Non-Small Cell Lung Cancer with stereotactic body radiation therapy.

Study participants will receive standard of care stereotactic body radiation therapy with either durvalumab or placebo (a ’dummy treatment’ that looks like the study drug but contains no active ingredient). The stereotactic body radiation therapy is a short course of radiation given over the course of the first 1-3 weeks of the study. Durvalumab or placebo will also be given at the start of the study, and then once a month for up to approximately 24 months.